Objective: Despite prolonged use of antipsychotic drug treatment, the prevalence of tardive dyskinesia (TD) in a Xhosa population has not been evaluated. This study was undertaken to assess the prevalence and identify possible factors, including antioxidant intake and smoking history, which may increase or reduce the risk of TD.
Method: One hundred two subjects who had been exposed to typical antipsychotic drugs for at least 6 months and were currently on an antipsychotic were screened for abnormal movements using the Abnormal Involuntary Movement Scale (AIMS) rating scale. Data about current and past antipsychotic therapy, diagnoses, smoking history, and dietary factors were gathered from the patient and from chart view.
Result: Twenty-eight and four-tenths percent of subjects met criteria for tardive dyskinesia. Years of treatment and total cumulative antipsychotic dose were significant predictors of TD. Subjects with higher total consumption of foods containing antioxidants had lower rates of TD, but only consumption of onions was significantly associated with reduced prevalence. TD was less prevalent in smokers, but this difference did not reach statistical significance. Age, sex, and psychiatric diagnosis did not predict presence of TD.
Conclusion: The result of this study indicate that TD in this population is more prevalent than previously believed within this local clinical context. Prolonged treatment and total antipsychotic drug exposure are important risk factors for TD in this population. Further study of the role of concurrent medications and dietary factors is indicated.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.schres.2004.10.009 | DOI Listing |
Am J Ther
January 2025
Department of Psychiatry, University of Health Sciences, Erzurum City Hospital, Erzurum, Turkey.
Neuropsychopharmacol Rep
March 2025
Department of Neurology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Aim: We aimed to create a rat model of drug-induced parkinsonism and tardive dyskinesia by chronic administration of haloperidol and examine the expression of direct and indirect pathway markers in the striatum of the model rats.
Methods: We treated 21 rats, 14 with haloperidol decanoate and 7 with placebo. The number of vacuous chewing movements per 2 min was counted, and haloperidol-treated rats were classified into two groups: mild and severe tardive dyskinesia.
Neurochem Res
January 2025
Department of Pharmacology, Central University of Punjab, Ghudda, Bhatinda, Punjab, 151401, India.
Antipsychotic medications are used to treat a psychological condition called 'Schizophrenia'. However, its long-term administration causes irregular involuntary motor movements, targeting the orofacial regions. Glycyrrhizic acid (GA) is a naturally occurring triterpene saponin glycoside obtained from the roots of the Glycyrrhiza glabra (liquorice) plant and well known for its antioxidant, antiapoptotic and neuroprotective abilities.
View Article and Find Full Text PDFClin Nucl Med
February 2025
From the Department of Nuclear Medicine and PET-Centre, Aarhus University Hospital, Aarhus, Denmark.
We present a case of a 66-year-old man, where 18F-FDG PET/CT revealed intense FDG uptake in the tongue, lips, cheeks, and chewing musculature and distinct activation of the somatosensory and motor cortex corresponding to the mouth and tongue. The patient suffered from buccolingual masticatory syndrome, characterized by tardive dyskinesia, meaning uncontrollable, repetitive movements of the tongue, lips, cheeks, and masticatory musculature. In this case, the buccolingual masticatory syndrome was caused by metoclopramide antiemetic treatment.
View Article and Find Full Text PDFFront Pharmacol
December 2024
Department of Clinical Psychology, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Background: Deutetrabenazine is a widely used drug for the treatment of tardive dyskinesia (TD), and post-marketing testing is important. There is a lack of real-world, large-sample safety studies of deutetrabenazine. In this study, a pharmacovigilance analysis of deutetrabenazine was performed based on the FDA Adverse Event Reporting System (FAERS) database to evaluate its relevant safety signals for clinical reference.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!